| Management target | Revenue 18.0% FY27 |
|---|
| Revenue growth | 9% YoY growth to ₹82 Cr, organic growth accelerating. |
|---|---|
| Margins | EBITDA margins expanded by 240 bps to 23% plus. |
| Demand visibility | Strong visibility in Gynaecology, Ortho, and Dermatology segments. |
| Management confidence | High confidence in 1.5x industry growth rate targets. |
Growth
Revenue grew 9% YoY to ₹82 Cr, while EBITDA and Net Profit grew 21% and 22% respectively.
Outlook
Equitas is expected to hit ₹100 Cr revenue and ₹10 Cr EBITDA by Year 2 post-integration.
Risks
High concentration in the 'Maintain' brand and historically longer working capital cycles in the hospital segment.
Last quarter's promises, checked
Delivered
- Guided double-digit growth → delivered 14.2% in Q4 (MAT 12.2%) (= BEAT)
- Guided 1.5x IPM growth → delivered 14.2% vs 10.5% industry (= BEAT)
- Guided 19% PAT growth → delivered 19% profit growth (= BEAT)
Earnings Call Transcript filed with NSE, NSE: JAGSNPHARM. Summary written with AI assistance from the document.
Jagsonpal Pharmaceuticals Ltd: key numbers
- Share price
- ₹242.29
- Market cap
- ₹1,598 Cr
- Revenue (annual)
- ₹287.2 Cr
- Net profit (annual)
- ₹43.08 Cr
- P/E (TTM)
- 35.1×Sector 50.4×
- Promoter holding
- 69.05%+1.16% QoQ
- FII holding
- 2.30%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jagsonpal Pharmaceuticals Ltd
All →Jagsonpal Pharmaceuticals Acquisition Worth ₹46.7 Cr
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
- Value
- ₹46.70 Cr
Jagsonpal Pharmaceuticals Annual General Meeting
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal Pharmaceuticals Investor Presentation: Key Takeaways
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals Q1 FY27 Results: Net Profit ₹13.2 Cr, Up 22.2% YoY
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
- Key figure
- Net profit ₹13.2 Cr · +22.2% YoY
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.
Jagsonpal Pharmaceuticals Earnings Call: Key Takeaways
Jagsonpal Pharmaceuticals reported strong FY26 results with 7% revenue growth and 19% PAT growth. Strategy focuses on an asset-light model, high-margin Rx brands, and shareholder returns via buybacks and dividends.